Skip to main content

Table 5 Multiple linear regression models of magnitude of HbA 1c reduction after combination therapy

From: Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

  Model 1 Model 2 Model 3
  β P β P β P
Drug group (0 = glibenclamide; 1 = acarbose) −0.113 0.410 −0.192 0.127 −0.183 0.126
Gender (0 = female; 1 = male) 0.206 0.110 - - - -
Age (years) 0.134 0.307 - - - -
Disease duration (years) −0.132 0.313 - - - -
BMI (kg/m2) −0.217 0.179 - - - -
HbA1c (%) 0.730 <0.001* 0.718 <0.001* 0.698 <0.001*
MISI −0.204 0.391 −0.273 0.234 - -
HOMA-IR 0.384 0.080 0.265 0.148 0.308 0.085
HOMA-β (%) 0.037 0.864 −0.036 0.835 - -
Insulinogenic index30 (pmol/mmol) 0.091 0.734 - - - -
AUCins120/AUCglu 120§(pmol/mmol) −0.379 0.258 −0.380 0.150 −0.199 0.249
DI120 1.009 0.045* 0.936 0.031* 0.696 0.030*
DI30 −0.574 0.226 −0.414 0.176 −0.358 0.142
  1. Multiple linear regression models with HbA1c reduction after combination therapy as the dependent variable. All independent variables were collected before randomization of the second-line OADs.
  2. *P < 0.005; § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
  3. DI, disposition index; HOMA-β, homeostasis model assessment β-cell function; HOMA-IR, homeostasis model assessment insulin resistance index;
  4. Incremental AUC, incremental area under curve during liquid mixed meal tolerance test; MISI, Matsuda insulin sensitivity index.